Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

LncRNA sequencing of human ovarian cancer cell SKOV3 after exposure to ginsenoside 20(S)-Rg3

ABSTRACT: lncRNA sequencing of human ovarian cancer cell SKOV3 after exposure to ginsenoside 20(S)-Rg3

PROVIDER: PRJNA484884 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

lncRNA sequencing of human ovarian cancer cell SKOV3 after exposure to ginsenoside 20(S)-Rg3

Project description:Ginsenoside 20(S)-Rg3, an active saponin monomer extracted from red ginseng, inhibits the malignancy of ovarian cancer cells. RNA-Seq analysis was used for deep sequencing of lncRNA to detected molecular mechanisms of 20(S)-Rg3.We identified 85 differentially expressed lncRNA influenced by 20(S)-Rg3, among which 67 lncRNAs were significantly decreased (fold change<0.5, p<0.05) including 12 ncRNAs and 55 pseudo genes, and 18 lncRNAs were significantly increased (fold change>1.5, p<0.05) including 3 ncRNAs, 14 pseudo genes and 1 unknown gene. This study provide a valuable resource for the discovery of lncRNAs related to anti-tumor mechanism of 20(S)-Rg3.

2021-02-16 | GSE118216 | GEO

MicroRNAs expression in 20(R)-ginsenoside Rg3-induced anti-angiogenesis

Project description:The angio-suppressive effect of 20(R)-ginsenoside Rg3 (Rg3-R) has been previously demonstrated, and microRNAs (miRNAs) are a vital group of small non-coding RNAs that function as post-transcriptional modulator of gene expression. Thus, using human umbilical vein endothelial cells (HUVEC) as model, we compared the microRNA (miRNA) expression profile of vascular endothelial growth factor (VEGF)-induced cells with the profile of the cell co-treated with VEGF and Rg3-R. Among the screened 553 human miRNAs, 6 up-regulated (miR-520h, miR-487b, miR-197, miR-524*, miR-342 and miR-219) and 3 down-regulated (miR-23a, miR-489 and miR-377) miRNAs were detected in Rg3-R treated vascular endothelial growth factor (VEGF)-induced HUVECs compared to VEGF alone. Real time RT-PCR was subsequently performed to verify the miRNA microarray result. Two condition experiment: VEGF-induced HUVEC and VEGF-induced HUVEC treated with Rg3-R. Three independent microarray experiments, with triplicate per microarray.

2011-09-09 | E-GEOD-31959 | biostudies-arrayexpress

MicroRNAs expression in 20(R)-ginsenoside Rg3-induced anti-angiogenesis

2011-09-10 | GSE31959 | GEO

Ginsenoside Rg3 epigenetically regulates cell-mediated immune pathway to inhibit proliferation of the MCF-7 breast cancer cell

Project description:Genome wide DNA methylation profiling of estrogene receptor postive breast cancer cell line MCF-7, treating Ginsoenoside Rg3. The Illumina Infinium Human Methylation EPIC v1.0 B2 Bead chip was used to obtain DNA methylation profiles across approximately 850,000 CpGs. This profiling indicates that Ginsenoside Rg3 induces epigenetic and cellular changes.

2017-12-31 | GSE99505 | GEO

Phosphoproteomics analysis of anti-cancer effects of ginsenoside Rg3 in human breast cancer cells

Project description:The breast cancer incidence has been increasing in China, with the earlier age of onset compared with Western countries. Traditional Chinese medicine has been provided as one of the major source of anti-cancer drugs. Ginseng is one of the most common traditional medicines in China. Ginsenosides, the saponins in the plant Panax (ginseng) are the major active components responsible for their chemopreventive effects from cancer. However, the mechanisms by which ginsenosides exert their anti-cancer effect remain elusive. By combining TMT-based quantitation with TiO2-based phosphopeptide enrichment, we performed a quantitative analysis of the changes of the phosphoproteomes in ginsenoside Rg3-treated breast cancer MDA-MB-231 cells. We were able to quantitate 5,140 phosphorylation sites on 2,041 phosphoproteins. Our data show that the phosphorylation status of 13 sites was changed in MDA-MB-231 cells upon Rg3 treatment. The perturbed phosphoproteins are CPSF7, EEF2, HIRIP3, MAGED2, MPRIP, MYCBP2, PAWR, PPP1R12A, RANBP2, SEPT9, TMPO, and UFL1. These proteins are involved in various biological processes, including protein synthesis, cell division, and inhibition of NF-κB signaling. Our study revealed that Rg3 exerts its anti-cancer effects through a combination of different signaling pathways.

2018-01-08 | PXD003092 | Pride

LncRNA/mRNA expression in SKOV3/SKOV3_DDP/IOSE80

Project description:To determine the lncRNA and mRNA expression profile in SKOV3/SKOV3_DDP/IOSE80, we uesed lncRNA microArray analysis form Arraystar to examine the expression of lncRNAs and mRNAs in SKOV3/SKOV3_DDP/IOSE80.

2017-10-11 | GSE104776 | GEO

The Role of CD83 in ovarian cancer cell line SKOV3

Project description:We performed RNA-Seq of CD83 overexpression SKOV3 cells (OV_1, OV_2, OV_3), CD83 knockdown SKOV3 cells (KD_1, KD_2, KD-3), and control SKOV3 cells (NC_1, NC_2, NC_3) using BGISEQ-500 platform (BGI, China).

2019-01-14 | GSE125011 | GEO

Homo sapiens

Project description:MicroRNAs expression in 20(R)-ginsenoside Rg3-induced anti-angiogenesis

| PRJNA144995 | ENA

Expression data from ovarian cancer SKOV3 human cell line

Project description:CDCP1 and PLAGL2 have been shown to act as oncogenes in several cancer types but little is known about the molecular signalling underlying these processes in ovarian cancer cells. In this study we aim to find the downstream signalling upon their individual silencing in the human ovarian cancer cell line SKOV3. We used microarrays to detail the global programme of gene expression underlying CDCP1 and PLAGL2 signalling in the human ovarian cancer cell line SKOV3

2020-04-12 | GSE113115 | GEO

Sequencing in transcriptomes in Ovarian cancer cell line SKOV3 and bevacizumab-treated SKOV3

Project description:To investigate the possible mechanism of bevacizumab resistance in ovarian cancer ,we examined the changes in gene expression of SKOV3 before and after bevacizumab intervention. Results provide insight into molecular mechanisms of acquired resistance to bevacizumab in ovarian cancer.

2023-12-31 | GSE165419 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data